<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682705</url>
  </required_header>
  <id_info>
    <org_study_id>M16-063</org_study_id>
    <secondary_id>2018-000666-10</secondary_id>
    <nct_id>NCT03682705</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.</brief_title>
  <official_title>A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599 Combination) With a Background of Conventional Synthetic DMARDs in Subjects With Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study to evaluate safety and efficacy of ABBV-105 and ABBV-599 (ABBV-105
      plus upadacitinib) vs placebo on a background of conventional synthetic disease-modifying
      anti-rheumatic drugs (csDMARDS) for the treatment of signs and symptoms of Rheumatoid
      Arthritis (RA) at 12 weeks in biological disease-modifying anti-rheumatic
      drugs(bDMARD)-inadequate response (bDMARD-IR) or bDMARD-intolerant participants with
      moderately to severely active RA and to define optimal dose for further development.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2018</start_date>
  <completion_date type="Actual">March 26, 2020</completion_date>
  <primary_completion_date type="Actual">March 26, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Disease Activity Score (DAS) 28 (C-reactive protein [CRP])</measure>
    <time_frame>At Week 12</time_frame>
    <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 to 10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>The CDAI is validated measure of RA disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving Clinical Remission (CR)</measure>
    <time_frame>At Week 12</time_frame>
    <description>Clinical Remission is defined as DAS28 CRP &lt;2.6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving Low Disease Activity (LDA)</measure>
    <time_frame>At Week 12</time_frame>
    <description>LDA is defined as DAS28 CRP&lt;=3.2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR)20 response rate</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>ACR 20 response rate will be determined based on 20%or greater improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (Visual Analog Scale [VAS]), Patient's Global Assessment of Disease Activity (PtGA), Physician's Global Assessment of Disease Activity (PhGA), Health Assessment Questionnaire Disability Index (HAQ-DI), or high-sensitivity C-reactive protein (hsCRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in individual components of ACR response</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in DAS28(CRP)</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>The Disease Activity Score (DAS)28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in morning stiffness</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Duration of morning stiffness on numeric rating scale (from 0 to 10) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HAQ-DI</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>The HAQ DI is a patient-reported questionnaire. It includes the categories of dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. It asks patients about the amount of difficulty they experience in these activities as well as the use of aids and/or devices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving Minimal Clinically Important Difference (MCID) in change from baseline in HAQ-DI</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>It is defined as change from baseline in HAQ-DI ≤ -0.3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving European League Against Rheumatism (EULAR) Boolean remission</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>A EULAR remission reflects improvement in disease activity and attainment of a lower degree of disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Simplified Disease Activity Index (SDAI)</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>SDAI is validated measure of RA disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 50 response rate</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>ACR 50 response rate will be determined based on 50% or greater improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (Visual Analog Scale (VAS)), Patient's Global Assessment of Disease Activity (PtGA), Physician's Global Assessment of Disease Activity (PhGA), Health Assessment Questionnaire Disability Index (HAQ-DI), or high-sensitivity C-reactive protein (hsCRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 70 response rate</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>ACR 70 response rate will be determined based on 70% or greater improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (Visual Analog Scale (VAS)), Patient's Global Assessment of Disease Activity (PtGA), Physician's Global Assessment of Disease Activity (PhGA), Health Assessment Questionnaire Disability Index (HAQ-DI), or high-sensitivity C-reactive protein (hsCRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in DAS28 (Erythrocyte Sedimentation Rate (ESR))</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>The change in the Disease Activity Score (DAS)28 (erythrocyte sedimentation rate) from the baseline is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving ACR remission</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving upadacitinib placebo and ABBV-105 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving upadacitinib and ABBV-105 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving upadacitinib placebo and ABBV-105 dose C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving upadacitinib placebo and ABBV-105 dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving upadacitinib placebo and ABBV-105 dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving upadacitinib and ABBV-105 dose A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Upadacitinib tablet will be administered orally.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <other_name>ABT-494</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-105</intervention_name>
    <description>ABBV-105 capsule will be administered orally.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib placebo</intervention_name>
    <description>Upadacitinib placebo tablet will be administered orally.</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-105 placebo</intervention_name>
    <description>ABBV-105 placebo capsule will be administered orally.</description>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA for &gt;=3 months based on the 2010 ACR/EULAR classification criteria for
             RA.

          -  Participant meets the following minimum disease activity criteria:

          -  &gt;=6 swollen joints (based on 66 joint counts) and &gt;=6 tender joints (based on 68 joint
             counts) at Screening and Baseline Visits

          -  hsCRP &gt;=3 mg/L (central lab) at Screening Visit.

          -  Participants must have been treated for &gt;=3 months with &gt;=1 bDMARD therapy but
             continue to exhibit active RA or had to discontinue due to intolerability or toxicity,
             irrespective of treatment duration.

          -  Participants must have been receiving csDMARD therapy &gt;=3 months and on a stable dose
             for &gt;=4 weeks prior to the first dose of study drug.

          -  Participants must have discontinued all bDMARDs prior to the first dose of study drug.

        Exclusion Criteria:

          -  Participant have prior exposure to any Janus Kinase (JAK) inhibitor for greater than 2
             weeks (including but not limited to upadacitinib, tofacitinib, baricitinib, and
             filgotinib). A washout period of &gt;= 30 days is required for any JAK inhibitor prior to
             the first dose of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheum Assoc of North Alabama /ID# 167382</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis &amp; Rheum Research /ID# 167446</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SunValley Arthritis Center, Lt /ID# 213073</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis and Rheum Researc /ID# 167448</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare /ID# 167379</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Purushotham, Akther &amp; Roshan K /ID# 168121</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valerius Medical Group /ID# 168123</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Rheumatology /ID# 167976</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Center of San Diego /ID# 170690</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128-2549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iraj Sabahi Research, Inc /ID# 201923</name>
      <address>
        <city>Turlock</city>
        <state>California</state>
        <zip>95382-2007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Rheum Clin Trials Inc. /ID# 167459</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research /ID# 205731</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Consultants of De /ID# 208238</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Arthritis and Osteo /ID# 208111</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Res of West FL, Inc. /ID# 167462</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants, LLC /ID# 167376</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713-2260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Clinical Research /ID# 167982</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakes Research, LLC /ID# 170660</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kendall South Medical Center, Inc. /ID# 206857</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33185-5948</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medallion Clinical Research Institute, LLC /ID# 201710</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheum Assoc of Central FL /ID# 170858</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HMD Research LLC /ID# 208381</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Research - Ormond /ID# 170864</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Research /ID# 167453</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center, Inc. /ID# 170695</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integral Rheumatology &amp; Immunology Specialists /ID# 206724</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BayCare Medical Group /ID# 170860</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anthony Comprehensive Rese /ID# 170668</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research West FL /ID# 169099</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research /ID# 206280</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613-1244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FL Med Clinic, PA /ID# 206279</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Arthritis Researc /ID# 170694</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials /ID# 167471</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Special /ID# 167468</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deerbrook Medical Associates /ID# 207098</name>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRN of Kansas /ID# 167985</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis &amp; Diabetes Clinic, Inc. /ID# 170682</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mansfield Health Center /ID# 167372</name>
      <address>
        <city>Mansfield</city>
        <state>Massachusetts</state>
        <zip>02048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Care /ID# 167367</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>June DO, PC /ID# 170670</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beals Instititute /ID# 170658</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates /ID# 209075</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Med Clinics /ID# 167377</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clayton Medical Associates dba Saint Louis Rheumatology /ID# 170650</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63119-3845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Research Collaboration (PRC) /ID# 200480</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dhmc /Id# 167476</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocean Rheumatology /ID# 170673</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteo Assoc /ID# 167443</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research, PLLC /ID# 167374</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210-8508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EmergeOrtho, P.A. /ID# 209154</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Fear Arthritis Care /ID# 167413</name>
      <address>
        <city>Leland</city>
        <state>North Carolina</state>
        <zip>28451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizons Clinical Research /ID# 170862</name>
      <address>
        <city>Blue Ash</city>
        <state>Ohio</state>
        <zip>45242-3763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marietta Memorial Hospital /ID# 210968</name>
      <address>
        <city>Marietta</city>
        <state>Ohio</state>
        <zip>45750-1635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STAT Research, Inc. /ID# 200485</name>
      <address>
        <city>Vandalia</city>
        <state>Ohio</state>
        <zip>45377-9464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research Oklahoma /ID# 167370</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103-2400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Ctr Reading /ID# 170708</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Inst /ID# 167366</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Arthritis and Rheumatology /ID# 206699</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amarillo Ctr for Clin Research /ID# 200484</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc. /ID# 167475</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Universal Res Assoc /ID# 209252</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arth and Osteo Clin Brazo Valley /ID# 209401</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research /ID# 167458</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Clin Res Ctr /ID# 167474</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Clinic of Houston /ID# 203689</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research /ID# 207059</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Texas Clinical Research /ID# 205732</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410-1198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SW Rheumatology Res. LLC /ID# 167383</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Universal Research Association /ID# 209253</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024-5283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute /ID# 170667</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management /ID# 200481</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research /ID# 167444</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Clinic /ID# 167407</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tidewater Physicians Medical Center /ID# 210884</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606-4434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Washington Arthritis C /ID# 205821</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <zip>98021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest, PLLC /ID# 200479</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology and Pulmonary cli /ID# 170863</name>
      <address>
        <city>Beckley</city>
        <state>West Virginia</state>
        <zip>25801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Rheumatology and Immunotherapy Center /ID# 167385</name>
      <address>
        <city>Franklin</city>
        <state>Wisconsin</state>
        <zip>53132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CUB Hospital Erasme /ID# 201965</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale</state>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc /ID# 201756</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Ghent /ID# 201757</name>
      <address>
        <city>Ghent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven /ID# 201927</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Assoc /ID# 207299</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5M 0H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic /ID# 202126</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIADS Research Co Ltd /ID# 202125</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3N 0K6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Rheumatology /ID# 202124</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hosp.-Toronto /ID# 202652</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Latha Naik /ID# 212972</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatolog s.r.o. /ID# 202610</name>
      <address>
        <city>Jihlava 1</city>
        <state>Jihlava</state>
        <zip>586 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav Praha /ID# 202142</name>
      <address>
        <city>Prague 2</city>
        <state>Praha 2</state>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie MUDr. Klara Sirova /ID# 205185</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Czech a.s /ID# 202144</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 202439</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház /ID# 202441</name>
      <address>
        <city>Nyíregyháza</city>
        <state>Szabolcs-Szatmar-Bereg</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revita Reumatologiai Rendelo /ID# 202438</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C-MED/CMED Rehabilitációsközpont /ID# 205804</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Medical Center Orvosi-es Fogorvosi Kozpont /ID# 202437</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Kliniczne /ID# 206473</name>
      <address>
        <city>Cracow</city>
        <state>Malopolskie</state>
        <zip>30-149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McBk Sc /Id# 212575</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <state>Mazowieckie</state>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NBR Polska /ID# 206476</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>00-465</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Daniluk, Nowak Sp.j. /ID# 212576</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatika - Centrum Reumatologii NZOZ /ID# 206472</name>
      <address>
        <city>Warsaw</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group, PSC /ID# 167983</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Un. Marques de Valdecilla /ID# 202133</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Clinico San Carlos /ID# 202135</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Malaga /ID# 202137</name>
      <address>
        <city>Málaga</city>
        <state>Malaga</state>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comple Hosp Univ de A Coruna /ID# 202140</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau /ID# 206535</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona /ID# 206575</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Basurto /ID# 206462</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Nieves /ID# 209705</name>
      <address>
        <city>Granada</city>
        <zip>18013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe /ID# 202139</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 201976</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford /ID# 201974</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warrington + Halton Hosp NHS /ID# 206002</name>
      <address>
        <city>Warrington</city>
        <zip>WA5 1LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Ireland</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABBV-105</keyword>
  <keyword>Upadacitinib</keyword>
  <keyword>ABBV-599</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

